| Security Name | Ticker | % of Net Assets |
|---|---|---|
| ABBVIE INC | ABBV | 7.70% |
| AMGEN INC. | AMGN | 5.55% |
| GILEAD SCIENCES, INC. | GILD | 4.82% |
| VERTEX PHARMACEUTICALS | VRTX | 4.11% |
| REGENERON PHARMACEUTICALS | REGN | 3.51% |
| ALNYLAM PHARMACEUTICALS | ALNY | 2.97% |
| INSMED INC | INSM | 2.88% |
| CORTEVA INC | CTVA | 2.46% |
| NATERA INC | NTRA | 2.16% |
| ASTRAZENECA PLC ADR | AZN | 2.07% |
| BIOGEN IDEC, INC. | BIIB | 1.91% |
| ILLUMINA INC | ILMN | 1.86% |
| INCYTE CORP | INCY | 1.84% |
| ROYALTY PHARMA PLC- CL A | RPRX | 1.78% |
| GUARDANT HEALTH INC | GH | 1.78% |
| BEONE MEDICINES LTD-ADR | BGNE | 1.76% |
| AVIDITY BIOSCIENCES INC | RNA | 1.62% |
| NEUROCRINE BIOSCIENCES IN | NBIX | 1.58% |
| EXACT SCIENCES | EXAS | 1.51% |
| IONIS PHARMACEUTICALS, IN | IONS | 1.45% |
| BRIDGEBIO PHARMA INC | BBIO | 1.41% |
| ARGENX SE - ADR | ARGX | 1.40% |
| REVOLUTION MEDICINES INC | RVMD | 1.40% |
| ROIVANT SCIENCES LTD | ROIV | 1.38% |
| VIATRIS INC | VTRS | 1.38% |
| UNITED THERAPEUTICS CORP | UTHR | 1.35% |
| EXELIXIS, INC. | EXEL | 1.31% |
| JAZZ PHARMACEUTICALS PLC | JAZZ | 1.28% |
| ALKERMES PLC | ALKS | 1.22% |
| BIOMARIN PHARMACEUTICAL | BMRN | 1.19% |
| MODERNA INC | MRNA | 1.12% |
| CYTOKINETICS INC | CYTK | 1.12% |
| HALOZYME THERAPEUTICS INC | HALO | 1.04% |
| ARROWHEAD PHARMACEUTICALS | ARWR | 1.03% |
| BIONTECH SE-ADR | BNTX | 1.03% |
| VAXCYTE INC | PCVX | 1.02% |
| PTC THERAPEUTICS | PTCT | 1.01% |
| PROTAGONIST THER | PTGX | 1.00% |
| CRISPR THERAPEUTICS AG | CRSP | 1.00% |
| AXSOME THERAPEUT | AXSM | 1.00% |
| VIKING THERAPEUTICS INC | VKTX | 0.96% |
| LEGEND BIOTECH CORP-ADR | LEGN | 0.93% |
| AKERO THERAPEUTICS INC | AKRO | 0.88% |
| NUVALENT INC-A | NUVL | 0.87% |
| CRINETICS PHARMACEUTICALS | CRNX | 0.85% |
| TG THERAPEUTICS | TGTX | 0.85% |
| VERACYTE INC | VCYT | 0.81% |
| MEDPACE HOLDINGS | MEDP | 0.81% |
| DYNE THERAPEUTICS INC | DYN | 0.72% |
| IDEAYA BIOSCIENCES INC | IDYA | 0.70% |
| ADMA BIOLOGICS INC | ADMA | 0.69% |
| AMICUS THERAPEUTICS INC | FOLD | 0.69% |
| ULTRAGENYX PHARM | RARE | 0.66% |
| ACADIA PHARMACEUTICALS IN | ACAD | 0.65% |
| ARCELLX INC | ACLX | 0.63% |
| IMMUNOVANT INC | IMVT | 0.60% |
| AGIOS PHARMACEUT | AGIO | 0.58% |
| MADRIGAL PHARMAC | MDGL | 0.57% |
| TWIST BIOSCIENCE CORP | TWST | 0.56% |
| SUMMIT THERAPEUTICS INC | SMMT | 0.56% |
| BEAM THERAPEUTICS INC | BEAM | 0.55% |
| DENALI THERAPEUT | DNLI | 0.53% |
| RECURSION PHARMACEUTICALS | RXRX | 0.52% |
| APELLIS PHARMACE | APLS | 0.51% |
| SAREPTA THERAPEU | SRPT | 0.50% |
| ASCENDIS PHA-ADR | ASND | 0.49% |
| DYNAVAX TECHNOLOGY | DVAX | 0.47% |
| CELLDEX THERAPEUTICS INC | CLDX | 0.47% |
| KRYSTAL BIOTECH INC | KRYS | 0.47% |
| NOVAVAX INC | NVAX | 0.40% |
| INTELLIA THERAPE | NTLA | 0.36% |
| SOLENO THERAPEUTICS INC | SLNO | 0.35% |
| IOVANCE BIOTHERAPEUTICS | IOVA | 0.20% |
| Other (Cash, derivatives and other liabilities) | 0.60% | |
| Total: | ||
Read a prospectus and summary prospectus (if available) carefully before investing. It contains the investment objective, risks charges, expenses and the other information, which should be considered carefully before investing. To obtain a prospectus and summary prospectus (if available) click here or call 800.820.0888.
Investing involves risk, including the possible loss of principal.
Guggenheim Investments represents the following affiliated investment management businesses of Guggenheim Partners, LLC: Guggenheim Partners Investment Management, LLC, Security Investors, LLC, Guggenheim Funds Distributors, LLC, Guggenheim Funds Investment Advisors, LLC, Guggenheim Corporate Funding, LLC, Guggenheim Wealth Solutions, LLC, Guggenheim Partners Europe Limited, Guggenheim Partners Japan Limited, GS GAMMA Advisors, LLC, and Guggenheim Private Investments, LLC.
© 2025 Guggenheim Investments. All Rights Reserved.
Research our firm with FINRA Broker Check.
• Not FDIC Insured • No Bank Guarantee • May Lose Value
This website is directed to and intended for use by citizens or residents of the United States of America only. The material provided on this website is not intended as a recommendation or as investment advice of any kind, including in connection with rollovers, transfers, and distributions. Such material is not provided in a fiduciary capacity, may not be relied upon for or in connection with the making of investment decisions, and does not constitute a solicitation of an offer to buy or sell securities. All content has been provided for informational or educational purposes only and is not intended to be and should not be construed as legal or tax advice and/or a legal opinion. Always consult a financial, tax and/or legal professional regarding your specific situation. Investing involves risk, including the possible loss of principal.